Title: The Voice of the Patient - Friedreich's Ataxia

Authors: Friedreich's Ataxia Research Alliance: Jane Larkindale, DPhil, Jennifer Farmer, MS, CGC, Katie Schultz, Ronald Bartek, Consultant: James Valentine, JD, MHS

Collaborators: MDA: Lianna Orlando, PhD, Kristin Stephenson, MHA, JD, Jennifer Tripp, NAF: Susan Hagen, FARA: Kyle Bryant, Felicia DeRosa, Jamie Young.

Disclosures: FARA receives funding from pharmaceutical companies in the form of sponsorship of scientific meetings and events, including support for this patient focused drug development meeting. In accepting this money, FARA explicitly stated that the sponsoring company has not control over meeting content or other FARA activities. James Valentine is employed by Hyman, Phelps & McNamara, P.C., a law firm that represents sponsors who are developing drugs for rare diseases as well as rare disease patient advocacy organizations, including FARA. Other individual authors have nothing to disclose.

Funding: The meeting was co-funded by FARA, Muscular Dystrophy Association, National Ataxia Foundation and CureFA Foundation. Sponsorship of the meeting was also provided by Takeda Pharmaceuticals, Reata Pharmaceuticals, Horizon Pharma, Agilis Biotherapeutics, Pfizer, Retrotope, Catabasis Pharmaceuticals and Jupiter Orphan Therapeutics. Company funds were used to support the meeting as a whole and put towards support of some patient travel through a scholarship application process overseen by FARA. FARA funding supported the writing of the report.

Version Date: August 20th, 2017

Revisions and modifications: This document has not been revised and/or modified in any way after the version date listed above and on the cover page.

The submitters have all necessary permissions to submit this external resource and linking from the FDA website will not violate the proprietary rights of others.

Point of Contact: Jane Larkindale, DPhil. VP of Research Development for FARA. Jane.larkindale@curefa.org.